Anshul Maheshwari Sells 4,937 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) CFO Anshul Maheshwari sold 4,937 shares of the company's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $19.02, for a total transaction of $93,901.74. Following the completion of the transaction, the chief financial officer now owns 232,069 shares of the company's stock, valued at $4,413,952.38. This trade represents a 2.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Anshul Maheshwari also recently made the following trade(s):

• On Wednesday, May 7th, Anshul Maheshwari sold 4,937 shares of SI-BONE stock. The stock was sold at an average price of $17.00, for a total transaction of $83,929.00.

SI-BONE Stock Up 0.1%

SI-BONE stock traded up $0.03 during trading hours on Tuesday, hitting $19.48. The stock had a trading volume of 24,788 shares, compared to its average volume of 373,764. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $829.93 million, a P/E ratio of -21.17 and a beta of 0.82. SI-BONE, Inc. has a 12-month low of $11.70 and a 12-month high of $20.05. The stock's 50-day moving average price is $14.92 and its 200-day moving average price is $15.08.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.09. The firm had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Equities research analysts anticipate that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SIBN has been the topic of a number of research reports. Truist Financial lifted their target price on shares of SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th.

Institutional Investors Weigh In On SI-BONE

Hedge funds and other institutional investors have recently made changes to their positions in the company. Nuveen LLC purchased a new position in SI-BONE during the 1st quarter valued at about $18,605,000. First Light Asset Management LLC raised its position in SI-BONE by 41.8% during the 1st quarter. First Light Asset Management LLC now owns 1,612,408 shares of the company's stock worth $22,622,000 after buying an additional 475,426 shares during the last quarter. Silvercrest Asset Management Group LLC increased its holdings in shares of SI-BONE by 21.9% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock valued at $27,392,000 after purchasing an additional 350,970 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of SI-BONE by 11.1% during the 1st quarter. American Century Companies Inc. now owns 2,642,322 shares of the company's stock valued at $37,072,000 after purchasing an additional 264,254 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in shares of SI-BONE by 55.0% during the 1st quarter. Victory Capital Management Inc. now owns 631,568 shares of the company's stock valued at $8,861,000 after purchasing an additional 224,190 shares in the last quarter. Hedge funds and other institutional investors own 98.11% of the company's stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.